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Mutations in the gene that encodes the lysosomal exoglycohydrolase, a-galactosidase A (a-GalA), cause Fabry
disease, an X-linked recessive inborn error of glycosphingolipid catabolism. Human a-GalA is one of the rare
mammalian genes that has its polyadenylation signal in the coding sequence and lacks a 3′ untranslated region
(UTR). We identiﬁed two novel frameshift mutations, 1277delAA (del2) and 1284delACTT (del4), in unrelated
men with classical Fabry disease. Both mutations occurred in the 3′ terminus of the coding region and obliterated
the termination codon, and del2 also altered the polyadenylation signal. To characterize these mutations, 3′ rapid
ampliﬁcation of cDNA ends (RACE) and polymerase chain reactions (PCR) were performed, and the amplicons
were subcloned and sequenced. Both mutations generated multiple transcripts with various lengths of 3′ terminal
sequences, some elongating ∼1 kb. Mutant transcripts were classiﬁed as follows: type I transcripts had terminal
in-frame thymidines that created termination codons when polyadenylated, type II had downstream termination
codons within the elongated a-GalA sequence, and type III, the most abundant, lacked termination codons at their
3′ ends. To determine if the type III transcripts were degraded by the recently described cytosolic messenger RNA
degradation pathway for messages lacking termination codons, northern blot analysis was performed. However,
the ﬁnding of similar levels of nuclear and cytoplasmic a-GalA mRNA in normal and patient lymphoblasts suggested
that mRNA degradation did not result from either mutation. Expression of representative transcript types revealed
differences in intracellular localization and/or protein stability and catalytic activity, with most mutant proteins
being nonfunctional. Characterization of these 3′ mutations identiﬁed a novel molecular mechanism causing classical
Fabry disease.
Introduction
Fabry disease (MIM 301500) is an X-linked recessive
inborn error of glycosphingolipid catabolism resulting
from the deﬁcient activity of the lysosomal exoglyco-
hydrolase, a-galactosidase A (a-GalA) (EC 3.2.1.22).
The enzymatic defect results in the progressive accu-
mulation of neutral glycosphingolipids with terminal a-
linked galactosyl moieties (primarily globotriaosylcer-
amide [GL-3]) in the plasma and in the lysosomes of
cells throughout the body (Desnick et al. 2001). In clas-
sically affected males with little, if any, a-GalA activity,
the accumulation of GL-3, particularly in the vascular
endothelium, leads to the major clinical manifestations,
including acroparesthesias, angiokeratoma, hypohidro-
sis, and the characteristic corneal and lenticular opaci-
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ties. Onset usually occurs in childhood or adolescence,
and, with advancing age, vascular complications of the
heart, kidney, and brain lead to early demise. In contrast,
atypical variants, who have low levels of residuala-GalA
activity, lack the typical manifestations and present later
in life, with major symptoms limited to the heart (von
Scheidt et al. 1991; Nakao et al. 1995; Desnick et al.
2001).
The complete genomic and cDNA sequences of the
human a-GalA gene have been determined (Bishop et al.
1986; Kornreich et al. 1989). This gene is unique among
eukaryotic genes, because it lacks a 3′ UTR, except for
rare variant mRNAs having short 3′ UTRs of 6 or 7 nt
(Bishop et al. 1988). The polyadenylation signal (pAS)
is in the coding sequence, and the termination signal is
in the last codon. To date, 1300 disease-causing a-GalA
mutations have been identiﬁed, including missense mu-
tations, small deletions/insertions, splice mutations, and
large gene rearrangements (Desnick et al. 2001). Despite
the marked molecular heterogeneity of this disease,
mutations that affect 3′-end formation have not been
described.
In most eukaryotic mRNAs, 3′-end formation is gen-
erated through endonucleolytic cleavage and addition
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of the poly(A) tail. In mammalian cells, this reaction
depends on three elements that deﬁne the core pAS: the
consensus AAUAAA hexonucleotide or some functional
variant, a degenerate U-rich or GU-rich sequence 10–30
nt downstream of the cleavage site (the downstream
element [DSE]), and the cleavage site itself, which be-
comes the point of poly(A) addition, that is, the poly(A)
site (Zhao et al. 1999). The poly(A) tail presumably
enhances the translation and stability of mRNAs (Sachs
et al. 1997; Preiss and Hentze 1998), as well as con-
tributing to their transport from the nucleus to the cy-
toplasm (Eckner et al. 1991; Huang and Carmichael
1996; Hilleren et al. 2001). Defects in 3′-end formation
can therefore have profound effects on gene expression
and may cause disease. Only a few human pAS muta-
tions have been reported elsewhere; they include mu-
tations in the a- and b-globin (Orkin et al. 1985; Rund
et al. 1992; Harteveld et al. 1994), the IL2RG (Hsu et
al. 2000), and the FOXP3 genes (Bennett et al. 2001),
all four of which have 3′ UTRs. Most of these pAS
mutations caused disease by reducing the levels of their
respective mature mRNAs.
Here, we describe two novel a-GalA mutations that
altered 3′-end formation in unrelated men with classical
Fabry disease. Both lesions were small deletions that
caused frameshift mutations at the 3′ terminus of the
gene, thereby obliterating the termination codon. Sur-
prisingly, both mutations resulted in multiple transcripts
with various 3′ lengths. Of note, many of the mutant
transcripts were cleaved at upstream and distant down-
stream sites, which had alternative pAS motifs. To fur-
ther characterize these disease-causing mutations, the
stability of the mutant transcripts in each patient’s cul-
tured lymphoblasts was analyzed, and the expressed ac-
tivity and subcellular localization of representative mu-
tant proteins were determined in COS-7 cells.
Subjects, Material, and Methods
Probands
Proband 1 was a 51-year-old Swedish man who had
onset of acroparesthesias at 10 years of age and subse-
quently had gastrointestinal manifestations, including
abdominal pain and chronic diarrhea. He developed hy-
pertrophic cardiomyopathy and, because of an atrioven-
tricular block II–III, required a pacemaker. His renal func-
tion was normal, with only a trace of urinary protein. His
a-GalA activities in plasma and cultured lymphoblasts
were 0.4 nmol/h/ml (normal mean  SD 21.6  6.4
nmol/h/ml) and 1.8 nmol/h/mg protein (normal mean 
SD 86.3  15.8 nmol/h/mg protein), respectively.
Proband 2 was a 51-year-old Brazilian man who had
childhood onset of acroparesthesias, angiokeratoma, hy-
pohidrosis, and corneal opacities. He had microalbu-
minuria, which may have been secondary to his diabetes
mellitus, but retained normal renal function. He had no
evidence of cardiac or cerebral involvement. His a-GalA
activities in plasma and cultured lymphoblasts were 0.4
nmol/h/ml and 1.7 nmol/h/mg, respectively.
Mutation Analysis
Peripheral blood was collected in EDTA from the pro-
bands after informed consent was obtained. Genomic
DNA was isolated and ampliﬁed, and mutation analysis
was performed as described elsewhere (Shabbeer et al.
2002). In brief, each of the a-GalA exons and ﬂanking
intronic sequences was PCR ampliﬁed from genomic
DNA. Each amplicon was then sequenced with an ABI
Prism 3700 Capillary Array Sequencer, using the ABI
Prism BigDye Terminator Ready Reaction Mix (Perkin-
Elmer-Cetus). Each mutation was conﬁrmed by repeat
PCR ampliﬁcation and sequencing of the opposite strand
and by cosegregation of the lesion and disease in other
family members.
RNA Isolation and Characterization of Mutant
Transcripts
Total RNA was isolated from control and patient lym-
phoblast cell lines, using TRI reagent (Molecular Re-
search Center). Polyadenylated RNA (poly[A] RNA)
was isolated using the Oligotex mRNA kit (Qiagen),
and, for each sample, 1.0 mg of poly(A) RNA was used
to perform 3′ rapid ampliﬁcation of cDNA ends rapid
ampliﬁcation of cDNA ends (RACE) with the SMART
RACE cDNA ampliﬁcation kit (Clontech). A gene-
speciﬁc primer near the end of exon 6 (5′-GACGTAAT-
TGCCATCAATCAGGACC-3′) and a nested universal
primer within the oligo(dT) anchor sequence (5′-CCTC-
AAGCTATGGTATCAACGCAGAGT-3′) were used to
amplify a fragment of ∼380 bp for the normal a-GalA
cDNA, with the precise length depending on the length
of the poly(A) tail. The PCR products were cloned into
PCRII-TOPO vectors, using the Topo TA cloning kit
(Invitrogen), and 50 clones were randomly selected to
be sequenced for each mutation. The different del2 and
del4 subclones were designated transcripts “A1–A20”
and “B1–B16,” respectively.
Subcellular Fractionation and Northern Analysis
Cultured control and patient lymphoblasts were
treated or untreated with 100mg/ml cycloheximide for 5
h, and subcellular fractionation of control and patient
lymphoblasts was performed as described elsewhere
(Frischmeyer et al. 2002), with the following modi-
ﬁcations: cultured lymphoblasts were washed in cold
PBS, pelleted by centrifugation at 200 g for 5 min at
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4C, and resuspended in hypotonic lysis buffer (10
mmol/L NaCl, 3 mmol/L MgCl2, 10 mmol/L Tris-HCl
[pH 7.4], 0.5%NP-40, 1 mmol/L dithiothreitol, and 400
U/ml RNase inhibitor [Roche Molecular Biochemicals]).
After vortexing and incubation on ice for 5 min, the
nuclei were pelleted by centrifugation at 800 g for 5 min
at 4C. mRNA was isolated immediately from the nu-
clear and cytoplasmic fractions, using TRI reagent (Mo-
lecular Research Center). For each cellular fraction, 5.0
mg of mRNA was loaded onto a gel containing 1.0%
agarose and 5.0% formaldehyde. After electrophoresis,
RNA was transferred onto a Hybond XL membrane
(Amersham Pharmacia Biotech) in 20# standard saline
citrate buffer. The ﬁlter was incubated at 80C for 2 h
and was UV irradiated and hybridized with a randomly
primed 32[P]-labeled full-length a-GalA cDNA probe. To
determine the integrity of the RNA, the membrane was
rehybridized with a 32[P]-labeled cDNA for human b-
actin. The intensity of each signal was estimated using
the National Institutes of Health Image program.
Generation of Mutant a-GalA Constructs
The full-length wild-type a-GalA cDNA was obtained
from normal lymphoblasts by 3′ RACE, using the sense
primer 3′-AGGTTAATCTTAAAAGCCCAGGTTAC-5′
and the nested universal primer (described above). After
Topo TA cloning, the insert was subcloned into the
pcDNA 3.0 expression vector (Invitrogen), and this con-
struct was designated “pcWT.” To generate the full-
length mutant a-GalA constructs—pcA2, pcA3, pcA6,
pcA7, pcA8, pcA12, pcA14, pcA16, pcA19 (del2), pcB1,
pcB3, pcB4, pcB6, pcB7, pcB10, and pcB14–pcB16
(del4)—a 1-kb fragment containing most of the wild-
type a-GalA gene from the 5′ end was digested out of
the pcWT and was spliced into the respective mutant
pCR-II TOPO plasmids, using KpnI restriction sites. The
full-length mutant a-GalA cDNAs were then subcloned
into the pcDNA 3.0 expression vector. All constructs
were conﬁrmed by sequencing. Note that the reverse
primer used for 3′ RACE contained three termination
codons, each in a different reading frame (ﬁg. 1A). Thus,
all cloned cDNAs were designed to terminate within this
primer sequence, regardless of their reading frame.
Cell Culture and Transient Transfections
Patient lymphoblasts were cultured as described else-
where (Anderson and Gusella 1984). COS-7 cells from
the American Type Culture Collection were maintained
in Dulbecco’s modiﬁed Eagle medium (Invitrogen) sup-
plemented with 10% fetal bovine serum and antibiotics
at 37C with 5% CO2. COS-7 cells were plated onto
35-mm six-well culture plates with or without coverslips
for immunoﬂuorescence microscopy and a-GalA en-
zyme assays, respectively. Plasmid DNA (1.0 mg) was
transfected into each well, using FuGene6 transfection
reagent (Roche Molecular Biochemicals), and incubated
at 37C for 48 h.
Protein Quantiﬁcation and a-GalA Enzyme Assays
a-GalA activity was determined using the ﬂuorogenic
substrate, 4-methylumbelliferyl-a-D-galactopyranoside
(Diagnostic Chemicals), as described elsewhere (Desnick
et al. 1973). N-acetylgalactosamine (0.1 mmol) (Amer-
sham Pharmacia Biotech) was used as an inhibitor of a-
galactosidase B activity. For enzyme assays in COS-7
cells, transient transfections were performed as described
above, and cells were harvested, lysed, and assayed for
a-GalA activity. Protein concentrations of the samples
were determined by use of the DC Protein Assay kit (Bio-
Rad). Enzymatic activity was expressed as nanomoles of
substrate protein hydrolyzed per hour per milligram. All
assays were done in triplicate from three separate trans-
fections, and, after subtraction of background, the mean
values were used to calculate the percent of wild-type
activity.
Immunoﬂuorescence Microscopy
COS-7 cells were grown on coverslips and transfected
as described above. After 48 h of incubation, cells were
washed with PBS and ﬁxed with 50% methanol/50%
acetone (vol/vol). Then the cells were washed extensively
in PBS, blocked in 3% BSA/0.2% Tween-20/PBS for 30
min, and incubated overnight at 4C with rabbit anti–
human a-GalA antibodies (Ioannou et al. 1998). The a-
GalA antibody solution was removed, and cells were
incubated with mouse anti–human LAMP2 antibodies
(Hybridoma Bank, University of Iowa) or mouse anti–
human BiP antibodies (BD Biosciences Pharingen) for 1
h at room temperature. After three washes in 1%Triton-
X/0.2% Tween-20/PBS, the cells were incubated with
donkey anti–rabbit IgG-FITC (Jackson Immuno Re-
search) and donkey anti–mouse IgG–Rhodamine Red
(Jackson Immuno Research) for 30 min at room tem-
perature. The coverslips were washed as described above
and were mounted onto a microscope slide. The slides
were observed under a Nikon Eclipse ﬂuorescence mi-
croscope equipped with a charged coupling device
camera.
Results
Identiﬁcation and Characterization of the a-GalA
Mutations
PCR ampliﬁcation and direct sequencing of the a-
GalA gene from genomic DNA isolated from probands
1 and 2 revealed a two-base deletion—1277delAA (des-
ignated “del2”), which altered the last nucleotide of the
pAS AUUAAA to AUUAAG—and a four-base dele-
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Figure 1 3′ RACE–PCR analysis, using normal and mutant lymphoblasts. A, Design of 3′ RACE–PCR. A gene-speciﬁc sense primer (P1)
at the end of exon 6 and a nested primer within the oligo(dT) anchor sequence (P2) were used. The antisense primer contained three separate
termination codons, all in different reading frames. B, 3′ RACE–PCR products analyzed on a 1.5% agarose gel. Lane 1, normal control; lane
2, 1277delAA; lane 3, 1284delACTT.
tion—1284delACTT (designated “del4”), which elimi-
nated the four bases before the termination codon. Se-
quencing of RT-PCR products conﬁrmed their respective
lesions and did not identify any other upstream altera-
tions. To characterize the mutant transcripts, 3′ RACE–
PCR was performed using mRNA extracted from cul-
tured lymphoblasts established from each proband. Elec-
trophoresis showed that the del2 mutation had a major
product that was slightly smaller than the wild-type
cDNA and had several minor larger cDNAs, whereas
the del4 product was similar in size to the wild-type
cDNA (ﬁg. 1B). These cDNAs were subcloned, and 50
randomly selected colonies were sequenced for each mu-
tation. Surprisingly, both mutations hadmultiple cDNAs
with various 3′ lengths, some being shorter than wild
type and others being elongated (ﬁg. 2). In contrast,
sequencing of 10 colonies for the wild-type 3′ RACE
cDNAs revealed seven subclones having no 3′ UTR and
only three subclones having six or seven additional nu-
cleotides before the poly(A) tail, as described elsewhere
(Bishop et al. 1988). The different del2 and del4 sub-
clones were designated transcripts “A1–A20” and “B1–
B16,” respectively.
The major del2 transcripts—A3, A4, and A6 (ﬁg.
2A)—were 5–14 nt shorter than wild type and accounted
for ∼40% of the transcripts. Only A8, which accounted
for 8% of del2 transcripts, used the same cleavage/poly-
adenylation site as wild-type a-GalA. Transcripts A1,
A2, A5, and A7 were within the range of 17 to 1
nt of the wild type, whereas transcripts A9–A15 were
elongated by 1–22 nt. Interestingly, ∼20% of the cloned
transcripts (A16–A20), were elongated by 1180 nt, the
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Figure 2 Mutant transcripts detected in the 1277delAA (A) and 1284delACTT (B) mutations. The natural polyadenylation signal,
AUUAAA, or mutated AUUAAG (del2) is indicated by an underline, and the alternative signal, AAUACA, is shown in italics. The original
termination codon is shown in bold. Sequences upstream of the original termination site are capitalized, whereas nonconsensus and elongated
sequences are in lowercase. The mutant transcripts were designated “A1–A20” (1277delAA) and “B1–B16” (1284delACTT), and their frequencies
among the 50 colonies are indicated, as well as transcript type. A bullet (•) indicates that the base was identical to the one above.
longest (A20) by ∼1 kb. Among these, A16, A18, and
A20 were followed by A-rich sequences and therefore
may have been derived through false priming of the 3′
RACE oligo(dT) primer (ﬁg. 3). In contrast, transcripts
A17 and A19 were not followed by A-rich motifs, sug-
gesting that these cleavage sites must be used in vivo.
Notably, transcripts A2 and A7 had terminal, in-frame
thymidines, which, if followed by the poly(A) tail, would
encode TAA, a de novo termination codon (designated
“type I” transcripts). The longer transcripts, A16–A20,
had termination codons that were ∼55 nt downstream
of the obliterated, wild-type poly(A) site (designated
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Figure 3 The elongated del2 mutant transcripts are cleaved at different downstream sites. Uppercase sequences are the coding region of
the human a-GalA gene, and the downward arrowhead () indicates the natural poly(A) site. The poly(A) sites of the mutant transcripts are
shown by insertion of the corresponding transcript numbers in parentheses. Consensus AAUAAA signals are shown in bold, and the DSEs are
underlined.
“type II” transcripts) (ﬁg. 4). However, most (∼70%) of
the del2 transcripts lacked termination codons at their
3′ ends (designated “type III” or “nonstop” transcripts).
In comparison with the variety of del2 transcripts, the
del4 transcripts were less diverse (ﬁg. 2B). The major
del4 transcripts, B7 and B10, were 6 and 7 nt longer
than the wild-type forms, respectively, and used the same
cleavage sites as the wild-type variant forms (Bishop et
al. 1988). Transcript B1, which was 36 nt shorter than
wild-type transcripts, was the shortest among the del2
and del4 transcripts. B2–B4 were 5–14 nt shorter than
wild type, whereas B5, B6, B8, B9, and B11–B15 were
4–23 nt longer. Transcript B1, as well as B16, which
shared the same cleavage site as A18, may have been
derived through false priming, since they were followed
by A-rich sequences. Transcripts B6 and B15 both had
a terminal, in-frame thymidine (type I), and B16 had a
termination codon ∼70 nt downstream of the obliterated
termination site (type II) (ﬁg. 4). The majority (∼90%)
of del4 transcripts lacked termination codons at their 3′
ends (type III).
Stability of the Mutant Transcripts
To determine whether the del2 and del4 type III tran-
scripts that lacked a termination codon were degraded
by the recently proposed “nonstop transcript decay”
pathway, the mRNAs in the nuclear and cytoplasmic
fractions of wild-type, del2, and del4 lymphoblasts were
isolated and assessed by northern hybridization. The a-
GalA mRNA levels (normalized to b-actin mRNA) in
the nuclear and cytoplasmic fractions were comparable
to—or somewhat higher than—those of the wild-type
mRNA (ﬁg. 5), even when the cells were treated with the
translational inhibitor, cycloheximide (data not shown)
(Frischmeyer et al. 2002. This indicated that the del2
and del4 mutant transcripts were stable and abundant.
The sizes of the mutant a-GalA mRNAs were essentially
the same as the normal transcript, and elongated tran-
scripts were undetectable from either the del2 or del4
mRNAs.
Expression Analysis of Mutant Constructs
The intracellular a-GalA activity and subcellular lo-
calization of the mutant proteins encoded by represen-
tative del2 and del4 mutant cDNAs were determined by
transient transfection in COS-7 cells. The mutant con-
structs had ﬁve different protein expression proﬁles, de-
pending upon whether or not their cDNAs ended with
a termination codon and the extent to which they were
elongated (table 1). The mutant proteins that were en-
coded by transcripts with in-frame terminal thymidines
(type I) and within the range of 15 to 5 nt of the
wild-type sequence were sorted to the lysosomes (ﬁg. 6a)
and had wild-type catalytic activity (designated “type I-
L”). These included the mutant proteins encoded by del2
transcripts A2 and A7 and del4 transcript B6 (table 1).
In contrast, the mutant protein synthesized by transcript
B15, which had an in-frame terminal thymidine but was
elongated by 23 nt, had only partial activity and was
retained in the endoplasmic reticulum (ER) (designated
“type I-ER”) (ﬁg. 6b). Mutant proteins encoded by tran-
scripts elongating 1180 nt, which had de novo termi-
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Figure 4 Elongation of the 1277delAA and 1284delACTT mutant proteins. Sequences are aligned by codons, and the corresponding
amino acid is shown below each codon. Termination codons are indicated by asterisks (*).
nation codons within their elongated a-GalA sequences
(type II), were retained in the ER, because of misfold-
ing, and had no catalytic activity. These included del2
transcripts A16–A20 and del4 transcript B16. The mu-
tant proteins synthesized by type III nonstop transcripts,
whose lengths were between 36 nt shorter and 7 nt
longer than those of the wild type, were transported to
the lysosomes but retained only partial activity (desig-
nated “type III-L”). These included del2 transcripts A3,
A6, and A8 and del4 transcripts B1, B3, B4, B7, and
B10. In contrast, the proteins produced by the longer
nonstop transcripts (17–22 nt longer than wild type) had
no catalytic activity and were undetectable by immu-
noﬂuorescence staining. These proteins were designated
“type III-X” (ﬁg. 6c) and included the mutant forms
expressed by del2 transcripts A12 and A14 and del4
transcript B14. Of note, the mutant constructs were de-
signed to have a termination codon within the reverse
primer sequence following their poly(A) tails (ﬁg. 1A).
Thus, nonstop transcripts were predicted to encode mul-
tiple lysines, because their poly(A) tails were translated,
and to terminate within the next 22 nt. To determine
whether poly(A) tract length affected protein expression,
nonstop transcripts that were identical to A6 and B7,
except for their poly(A) tail length, were selected and
expressed. The A6 and B7 transcripts originally used in
the expression studies had poly(A) tracts of ∼15 aden-
osines. Interestingly, when the poly(A) length was in-
creased from ∼15 to ∼60 adenosines, the cataclytic
activity was totally lost, and the A6- and B7-expressed
proteins became undetectable by immunoﬂuorescence
(table 2).
Discussion
Among eukaryotic genes, the human a-GalA gene is
unique, in that it has no 3′ UTR but retains the pAS in
the coding sequence and a termination signal in the last
codon. Therefore, the discovery of two deletions, del2
and del4, that cause classical Fabry disease was of in-
terest, and studies were conducted to characterize these
lesions. Both frameshift mutations resulted in multiple
mutant transcripts with different 3′ lengths in cultured
lymphoblasts. The del2 mutation, which occurred in the
last nucleotide of the AUUAAA pAS consensus sequence,
resulted in a more diverse population of transcripts, in
comparison with the del4 mutation, which did not di-
rectly modify the pAS. To our knowledge, this is the ﬁrst
report of 3′ mutations that display such a wide spectrum
of mutant transcripts.
This exceptional variety of mutant transcripts seems
to result from at least two different mechanisms, alter-
native pAS usage and aberrant cleavage-site selection.
For example, some of the mutant transcripts were
cleaved through activation of the alternative pAS, AAU-
ACA, which is located 28 nt upstream of the wild-type
termination codon (ﬁg. 2). Transcripts A1–A7 and
B2–B4 presumably used this upstream signal, since their
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Figure 5 Northern blot analysis of nuclear (Nuc) and cytoplasmic (Cyto) fractions in normal and patient lymphoblast lines (1277delAA
and 1284delACTT). a-GalA mRNA levels were normalized against b-actin, and the ratio of normalized mutant a-GalA to wild-type a-GalA
was calculated for each cellular compartment.
cleavage sites were within reasonable distance (12–26
nt) from the AAUACA hexonucleotide but were too
close (!10 nt) or were even further upstream of the
mutated AUUAAG (del2) or wild-type AUUAAA se-
quence. Most of the remaining transcripts most likely
used the mutated AUUAAG signal (in the case of
A8–A15) or wild-type AUUAAA signal (in the case of
B5–B15). However, since the two signals—AAUACA
and AUUAAA/AUUAAG (del2)—were very close to one
another, it was difﬁcult, for some mutant transcripts, to
pinpoint which of the two signals was actually used.
Thus, the del2 mutation, whose major transcripts (A3,
A4, and A6) used the upstream alternative AAUACA
hexonucleotide, resulted in more diverse transcripts,
compared with those resulting from the del4 mutation,
whose major transcripts (B7 and B10) used the wild-
type AUUAAA signal.
In addition to the upstream alternative pAS, the del2
mutation also seemed to have activated distant down-
stream pASs. This presumption is based on the fact that
both of the elongated del2 transcripts (A17 and A19)
had alternative AAUAAA hexonucleotides within 10–
30 nt upstream of their cleavage sites, as well as GU-
rich DSEs !30 nt downstream (ﬁg. 3). Two mutations
in the pAS of the human b-globin gene also have been
shown to cause similar read-through transcripts in vivo,
which elongated beyond the normal termination site
and were presumably cleaved at downstream alternative
poly(A) sites (Rund et al. 1992).
Studies have demonstrated that the efﬁciency of a
cleavage/polyadenylation site is deﬁned by the stability
of its interaction with the cleavage/polyadenylation
complex, particularly the cleavage polyadenylation–
specifying factor, with the AAUAAA hexonucleotide,
and the cleavage-stimulating factor, with the DSE
(Wahle and Ruegsegger 1999). The AAUAAA pAS is
highly conserved among mammals, whereas AUUAAA
is the most common variant signal (Wahle and Rueg-
segger 1999). The upstream alternative pAS, AAUACA,
is rare but is used in several mammalian genes (Beau-
doing et al. 2000), including the human genes spermi-
dine synthase (Myo¨ha¨nen et al. 1991) and type I keratin
(Marchuk et al. 1985) and in the a-subunit of the
photoreceptor cGMP phosphodiesterase (Pittler et al.
1990). In contrast, the mutated pAS of del2, AUUAAG,
was not identiﬁed in a pAS motif analysis of ∼5,600
ESTs, and it was suggested that either its efﬁciency is
low or it may even have a deleterious effect (Beaudoing
et al. 2000). It is probable that the del2 mutation, by
altering the last nucleotide of the AUUAAA sequence
to AUUAAG, caused instability of the pre-mRNA–
cleavage/polyadenylation complex and led to the rela-
tive strengthening of upstream and multiple down-
stream pASs, thereby resulting in a wider variety of
transcripts, compared with del4.
Another mechanism involved in the generation of mul-
tiple mutant transcripts is aberrant cleavage-site selec-
tion. Interestingly, even themutant transcripts that shared
the same pAS used multiple adjacent cleavage sites.
For instance, transcripts A8–A15 and B5–B15 most
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Table 1
In vitro a-GalA Activity and Subcellular Localization of Expressed Mutant Constructs in COS-7
Cells
Mutant
Construct
Transcript
Type
Length
(nt)
In-Frame
Thymidine
Termination
Codona
a-GalA Activity
(% WT)b
Subcellular
Localization
1277del2:
A2 I 15   116 Lysosome
A7 I 1   91 Lysosome
A16 II 181   0 ER
A19 II 706   0 ER
A3 III 14   17 Lysosome
A6 III 5   15 Lysosome
A8 III 0   18 Lysosome
A12 III 17   0 Undetectable
A14 III 19   0 Undetectable
1284del4:
B6 I 5   105 Lysosome
B15 I 23   12 ER
B16 II 335   0 ER
B1 III 36   25 Lysosome
B3 III 9   61 Lysosome
B4 III 5   26 Lysosome
B7 III 6   46 Lysosome
B10 III 7   5 Lysosome
B14 III 22   0 Undetectable
a All type III transcripts have artiﬁcial termination codons (ﬁg. 1A), which permit expression in
vitro (see “Discussion” section for details).
b WT p wild type.
likely used the AUUAAG (del2) or wild-type AUUAAA
signal. However, among these transcripts, only A8,which
accounted for 8% of all del2 transcripts, was cleaved/
polyadenylated at the same site as the wild type (ﬁg. 2A).
Aberrant cleavage-site selection may have resulted from
alteration of the relative positions of the AAUAAAmotif
and the DSE, since the distance between these two ele-
ments is believed to be an important cleavage site deter-
minant (Chen et al. 1995). Of note, both the del2 and
del4 mutations occur at STRs, presumably through back-
ward slipped strand mispairing. The del2 mutation oc-
curs in the last two of four consecutive adenosines,
whereas the del4 occurs in the second set of the repeated
nucleotides ACTT (ﬁg. 2). Although the del2 mutation
altered the pAS, del4 altered neither the pAS nor the
sequence surrounding the termination codon, since it
occurred within a repeated sequence. Thus, the del4
mutation provides further evidence that distance, more
than sequence context, is a crucial determinant of cleav-
age-site selection. Although there is no strict require-
ment for the precise sequences at which cleavage occurs,
previous studies have shown that there is a preference
of A 1 U 1 C k G (Chen et al. 1995). Analysis of the
mutant del2 and del4 transcripts, excluding those that
may have emerged through false priming (i.e., del2 A16,
A18, and A20 and del4 B1 and B16), shows that ∼70%
of del2 transcripts (A1, A3, A4, A6, A8, A15, A17, and
A19) were polyadenylated at sites adjacent to As, in-
dicating that this nucleotide preference may have con-
tributed to cleavage-site selection. In contrast, among
the del4 transcripts, only ∼30% (B2, B3, B10, B13, and
B14) were polyadenylated at sites adjacent to As. It
should be noted that these transcripts were probably
cleaved at the A nucleotide in vivo; thus, the ﬁrst aden-
osine of their poly(A) tails was derived from their tran-
scripts. Therefore, we propose that the del2 mutation
caused activation of several alternative pASs, as well as
aberrant cleavage, whereas the del4 mutation mainly
caused aberrant cleavage and resulted in multiple mu-
tant transcripts.
The fact that these mutant transcripts were stable was
signiﬁcant. Recently, a novel mRNA degradation path-
way in which transcripts lacking termination codons are
degraded by the cytoplasmic exosome was demon-
strated in yeast and mammalian cells (Frischmeyer et
al. 2002; van Hoof et al. 2002). This pathway was
referred to as “nonstop transcript decay.” The majority
of del2 and del4 transcripts lacked termination codons
at their 3′ terminals and, hence, were candidate sub-
strates for this degradation pathway. However, the
results of the northern blot analysis suggested that non-
stop decay did not occur in the del2 and del4 lympho-
blasts. Alternatively, nonstop decay may not have oc-
curred because of the unique 3′ end structure of the
human a-GalA gene. In addition, nonstop decay, a
translation-dependent pathway, would be impeded if
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Table 2
Effect of Poly(A) Tract Length on Protein Expression Pattern
MUTANT
CONSTRUCT
POLY(A)15 POLY(A)60
Activity
(% WT)a Localization
Activity
(% WT)a Localization
A6 15 Lysosome 0 Undetectable
B7 46 Lysosome 0 Undetectable
a WT p wild type.
Figure 6 Subcellular localization of mutant proteins. Representative mutant constructs were double stained with rabbit anti–human a-
GalA antibodies and either rabbit anti–human LAMP-2 (as the lysosome marker) antibodies (a) or rabbit anti–human BiP (the ER marker)
antibodies (b and c). Representative staining patterns of lysosomal (a), ER (b), and undetectable (c) proteins are shown.
aberrant 3′-end formation of the mutant transcripts
caused inefﬁcient translation in vivo.
To investigate whether the mutant cDNAswere trans-
latable and to determine their protein expression pat-
terns, representative mutant constructs were transfected
into COS-7 cells. These studies demonstrated that the
mutant cDNAs were translated, although the vast ma-
jority did not synthesize functional proteins (table 1).
The elongated type II transcripts with downstream ter-
mination codons produced misfolded proteins that were
retained in the ER. Although nonstop constructs with
short (∼15 nt) poly(A) tracts made proteins with partial
activity, the actual lengths of poly(A) tails of in vivo
type III transcripts were assumed to be normal (gen-
erally ∼200 adenosines), because the mutant transcripts
were transported to the cytoplasm (ﬁg. 5) (Eckner et al.
1991; Huang and Carmichael 1996; Hilleren et al.
2001). Therefore, two sets of type III transcripts that
use the same cleavage site but have longer (∼60 nt)
poly(A) tracts were expressed. Although the poly(A)60
transcripts were stable in COS-7 cells (data not shown),
they did not result in immunologically detectable pro-
teins. Presumably, the strong positive charge of multiple
lysines encoded by the poly(A) tail has trapped the pro-
tein in the ER membrane, thereby preventing release of
the nascent protein into the ER lumen and triggering
rapid degradation. Another possibility is that the mu-
tant protein with the longer poly(A) tract may have
resulted in a misfolded, highly unstable undimerized
polypeptide that was not recognized by the anti–a-GalA
antibodies. Hence, it is likely that the mutant proteins
encoded by the nonstop transcripts in vivo are highly
unstable and rapidly degraded.
Thus, only the type I-L transcripts, which had in-
frame terminal thymidines and were relatively short,
synthesized functional proteins with enzymatic activity
comparable to wild type. In the present studies, such
transcripts accounted for only 6% of the cDNAs in both
patients. The actual a-GalA activity in the lymphoblasts
of the two patients was 2.0% of the normal mean,
suggesting that these functional transcripts were even
less abundant in vivo. In addition, since a-GalA is a
homodimeric protein, it is possible that the few func-
tional transcripts may have encoded polypeptides that
dimerized with nonfunctional enzyme subunits, render-
ing the heterodimer noncatalytic or unstable.
In summary, we have identiﬁed two novel frameshift
mutations at the 3′ terminus of the a-GalA gene in un-
related men with classical Fabry disease. Bothmutations
resulted in multiple, stable transcripts with various 3′
lengths that were classiﬁed in three major types. Rep-
resentative mutant constructs were expressed, demon-
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strating that the vast majority of mutant polypeptides
were nonfunctional. These mutations reveal a novel mo-
lecular mechanism causing classical Fabry disease, and
they emphasize the molecular genetic heterogeneity of
this disorder. The present studies provide an increased
understanding of 3′-end formation and nonstop tran-
script decay in higher eukaryotes.
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